Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Small-molecule inhibitors targeting receptor tyrosine kinases (e.g., EGFR, ALK, ROS1, RET) have advanced non-small cell lung cancer (NSCLC) treatment by enabling an oncogene-centric classification.
• However, significant phenotypic diversity exists within these oncogene-driven NSCLC subgroups.
• Co-occurring genomic alterations, especially in tumor suppressor genes, are key drivers of this heterogeneity.

Purpose of the Study:

• To review the impact of co-mutations on the pathogenesis and biology of NSCLC.
• To explore how co-mutations influence microenvironmental interactions and therapeutic vulnerabilities.
• To assess challenges and opportunities presented by co-mutations for personalized therapy and precision immunotherapy.

Main Methods:

• Literature review of recent studies on NSCLC molecular classification and heterogeneity.
• Analysis of the role of co-occurring genomic alterations, particularly TP53 and LKB1/STK11 mutations.
• Synthesis of information on the effects of co-mutations on cancer hallmarks and therapeutic strategies.

Main Results:

• Co-occurring genomic alterations, notably in TP53 and LKB1/STK11, are critical determinants of molecular and clinical heterogeneity in oncogene-driven NSCLC.
• These co-mutations affect both tumor cell-intrinsic properties and non-cell-autonomous cancer hallmarks.
• Understanding co-mutations is essential for predicting treatment response and developing novel therapeutic approaches.

Conclusions:

• Co-mutations significantly contribute to the complexity and heterogeneity of NSCLC, impacting treatment outcomes.
• Personalized anticancer therapies and precision immunotherapy must account for these co-occurring genomic alterations.
• Further research into co-mutation biology is vital for advancing NSCLC treatment paradigms.